Sagimet Biosciences (SGMT) Treasury Shares (2022 - 2026)

Sagimet Biosciences' Treasury Shares history runs 5 years deep, the most recent figure standing at $1.1 million for Q1 2026.

• On a quarterly basis, Treasury Shares rose 2.61% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $1.1 million, a 2.61% increase from a year earlier, with the FY2025 full-year figure at $830077.0, down 1.69% from the prior year.
• Treasury Shares climbed to $1.1 million in Q1 2026 per SGMT's latest filing, from $830077.0 in the prior quarter.
• Across five years, Treasury Shares topped out at $1.4 billion in Q2 2022 and bottomed at $816937.0 in Q3 2025.
• The 5-year median for Treasury Shares is $1.1 million (2024), against an average of $458.6 million.
• Across the five-year window, Treasury Shares plunged 99.92% in 2024 and grew 2.61% in 2026, its largest moves.
• Year by year, Treasury Shares stood at $1.4 billion in 2022, then plunged by 99.92% to $1.1 million in 2023, then slipped by 25.43% to $844382.0 in 2024, then declined by 1.69% to $830077.0 in 2025, then soared by 35.78% to $1.1 million in 2026.
• Per Business Quant, the three latest SGMT Treasury Shares figures stand at $1.1 million (Q1 2026), $830077.0 (Q4 2025), and $816937.0 (Q3 2025).